Skip to content
Business
Prognosis

Merck Slumps on Covid Pill’s Lower Efficacy, FDA Scrutiny

  • New data on molnupiravir released ahead of advisory meeting
  • Agency staff ask about birth defects, genetic mutations
relates to Merck Slumps on Covid Pill’s Lower Efficacy, FDA Scrutiny

Source: Merck & Co.

Updated on

Merck & Co. shares sank after new data showed its Covid-19 pill was less effective than previously reported and U.S. regulators raised concerns about its safety and long-term effectiveness. 

Merck’s latest trial results, reported Friday from a larger population than its initial study, show that its pill reduced the risk of hospitalization or death among adults with mild to moderate disease by 30%. That was less than a previous estimate of 48%.